Impact of a Patient Support Program on Patient Adherence to Adalimumab and Direct Medical Costs in Crohn's Disease, Ulcerative Colitis, Rheumatoid Arthritis, Psoriasis, Psoriatic Arthritis, and Ankylosing Spondylitis.

Impact of a Patient Support Program on Patient Adherence to Adalimumab and Direct Medical Costs in Crohn's Disease, Ulcerative Colitis, Rheumatoid Arthritis, Psoriasis, Psoriatic Arthritis, and Ankylosing Spondylitis. J Manag Care Spec Pharm. 2017 Aug; 23(8):859-867.

View in: PubMed

subject areas

Adalimumab
Antirheumatic Agents
Arthritis, Psoriatic
Arthritis, Rheumatoid
Colitis, Ulcerative
Cost of Illness
Crohn Disease
Drug Costs
Female
Health Care Costs
Health Expenditures
Humans
Insurance Claim Review
Longitudinal Studies
Male
Managed Care Programs
Medication Adherence
Middle Aged
Psoriasis
Retrospective Studies
Spondylitis, Ankylosing
United States

authors with profiles

David T. Rubin